PRAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Praxis Precision Medicines Inc (PRAX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong long-term potential driven by its late-stage pipeline and positive sentiment around ulixacaltamide. Despite recent setbacks with vormatrigine, analysts remain optimistic about the company's future prospects.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 60.074, suggesting no overbought or oversold conditions. The stock is trading near its resistance level (R1: 281.821), with potential upside toward R2: 293.833. Moving averages are converging, signaling a potential trend continuation.
RBC Capital initiated coverage with an Outperform rating and a $449 price target, citing strong sales potential for ulixacaltamide.
Analysts highlight a large unmet need for essential tremor treatment and strong physician interest.
SwingMax sent an entry signal on 2026-06-12, with a 6.22% price increase since then.
Vormatrigine's Phase 2/3 POWER1 trial missed its primary endpoint, leading to a pause in the POWER2 trial.
Multiple analysts have lowered price targets due to the vormatrigine setback, though they remain optimistic about other pipeline assets.
No financial data available for the latest quarter.
Analysts are generally positive, with multiple Buy and Outperform ratings. Price targets range from $162 (Wedbush, Underperform) to $1,201 (H.C. Wainwright, Buy). Analysts remain optimistic about ulixacaltamide and other late-stage pipeline assets despite setbacks with vormatrigine.
